BMS-986158 clinical trials
BMS-986158 is named as an intervention in 2 current clinical trials in our USA, Spain, UK, Norway, Canada, Germany, France, Italy, Poland, South Korea, Australia and Israel registers. 1 is recruiting patients now. All registered phases are Phase 1/2. The lead sponsor is Bristol-Myers Squibb. The most-studied condition is Multiple Myeloma.
How BMS-986158 works
All drug targets →- Bromodomain and extra-terminal motif (BET) inhibitor InhibitorTarget: Bromodomain and extra-terminal motif (BET)✓ In ChEMBL and the Guide to Pharmacology
- Hematopoietic and lymphoid cell neoplasmPhase 1/2
- MyelofibrosisPhase 1/2
- Plasma cell myelomaPhase 1/2
- Brain neoplasmPhase 1
- LymphomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297458, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11757, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for BMS-986158
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of BMS-986158
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354 · Multiple Myeloma
|
Phase 1/2 | Recruiting | Bristol-Myers Squibb | UK, USA, Spain, Norway, Canada |
|
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
NCT04817007 · Myelofibrosis
|
Phase 1/2 | Active, closed | Bristol-Myers Squibb | USA, Germany, France, Spain, Italy, Poland, South Korea, Australia, Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with BMS-986158
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about BMS-986158 trials
How many clinical trials are testing BMS-986158?
2 current trials in our USA, Spain, UK, Norway, Canada, Germany, France, Italy, Poland, South Korea, Australia and Israel registers name BMS-986158 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are BMS-986158 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA, 1 with sites in Spain, 1 with sites in UK, 1 with sites in Norway and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors BMS-986158 clinical trials?
The lead sponsor is Bristol-Myers Squibb. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how BMS-986158 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BMS-986158 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BMS-986158 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.